Cocrystal Pharma (NASDAQ:COCP – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02), FiscalAI reports. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.10 million.
Cocrystal Pharma Stock Performance
Shares of COCP opened at $0.98 on Monday. The company’s fifty day moving average is $1.08 and its 200 day moving average is $1.10. Cocrystal Pharma has a fifty-two week low of $0.76 and a fifty-two week high of $2.03. The stock has a market capitalization of $18.88 million, a PE ratio of -1.29 and a beta of 1.60.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Weiss Ratings lowered shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. HC Wainwright reiterated a “buy” rating on shares of Cocrystal Pharma in a research report on Friday, October 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Featured Stories
- Five stocks we like better than Cocrystal Pharma
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
